OncoMatch/Clinical Trials/NCT05525338
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
Is NCT05525338 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Alectinib for drug monitoring.
Treatment: Alectinib — The ADAPT ALEC randomized controlled trial (RCT) is performed in patients with Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer (NSCLC). The RCT will compare the use of Therapeutic Drug Monitoring (TDM) and dose increases if alectinib 35 ng/Ml (arm A) with standard of care (arm B).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK rearrangement
Disease stage
Required: Stage IIIB, IV
Performance status
ECOG 0–4(Completely disabled)
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05525338 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ALK?
Yes, ALK rearrangement is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify